Table 1 Descriptive of demographic data, clinical characteristic, and severity of COVID-19 among our patients
From: Post COVID-19 syndrome in a prospective cohort study of Egyptian patients
Parameter measured | No. | % |
|---|---|---|
Age | ||
Mean ± SD, 55.46 ± 16.07 | ||
Median, 57 (45‑67) | ||
Range, (18‑94) | ||
Sex | ||
Male | 64 | 37.6% |
Female | 106 | 62.4% |
Comorbidities | ||
DM | 67 | 39.4% |
HTN | 73 | 42.9% |
IHD | 25 | 14.7% |
Cancer | 5 | 2.9% |
AID | 11 | 6.5% |
STROKE | 12 | 7.1% |
CRF | 7 | 4.1% |
CLD | 8 | 4.7% |
COPD | 9 | 5.3% |
COVID-19 symptoms | ||
Fatigue | 153 | 90.0% |
Fever | 118 | 69.4% |
Dyspnea | 117 | 68.8% |
Arthralgia | 127 | 74.7% |
Myalgia | 127 | 74.7% |
Cough | 122 | 71.8% |
Anosmia | 27 | 15.9% |
Rhinitis | 13 | 7.6% |
Headache | 55 | 32.4% |
Chest tightness | 70 | 41.2% |
Sore throat | 26 | 15.3% |
Nausea | 20 | 11.8% |
Diarrhea | 18 | 10.6% |
Loss of taste | 12 | 7.1% |
COVID-19 severity | ||
Mild | 95 | 55.9% |
Moderate | 47 | 27.6% |
Severe | 28 | 16.5% |